Study guide

9.3 Common Gynaecological Presentations & Gynaecological Oncology

Professional and Linguistic Assessments Board Part 1 PLAB 1

Track your progress as you read

Finished sections get a check mark.

1 Introduction

About the PLAB 1 Exam

2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies

1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies

3 Chapter 2: Cardiovascular Medicine & Vascular Disorders

2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease

4 Chapter 3: Respiratory Medicine

3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure

5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery

4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD

6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance

5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies

7 Chapter 6: Endocrinology & Metabolic Medicine

6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease

8 Chapter 7: Neurology & Neurosciences

7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders

9 Chapter 8: Psychiatry & Mental Health

8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health

10 Chapter 9: Obstetrics, Gynaecology & Sexual Health

9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence

11 Chapter 10: Paediatrics & Child Health

10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems

12 Chapter 11: Musculoskeletal Medicine & Rheumatology

11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders

13 Chapter 12: Dermatology, ENT & Ophthalmology

12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer

14 Chapter 13: Haematology, Oncology & Palliative Care

13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral

15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology

14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship

16 Chapter 15: Medical Ethics, Law & UK Clinical Practice

15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse

17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention

16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention

18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging

17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays

9.3 Common Gynaecological Presentations & Gynaecological Oncology

Key Takeaways Explain This Topic AI

Heavy Menstrual Bleeding (HMB) is categorized using the FIGO PALM-COEIN system; NICE NG88 designates the 52 mg levonorgestrel-releasing intrauterine system (LNG-IUS) as first-line medical therapy when contraception is acceptable.

Endometriosis and adenomyosis manifest with chronic pelvic pain, progressive cyclical dysmenorrhoea, deep dyspareunia, dyschezia, and subfertility; diagnostic laparoscopy with histological biopsy remains the gold standard for diagnosing endometriosis.

Polycystic Ovary Syndrome (PCOS) requires at least two of the three Rotterdam criteria (oligo/anovulation, clinical or biochemical hyperandrogenism, polycystic ovaries on TVUS); management prioritizes lifestyle-induced weight loss, cyclical progestogens or COCPs to prevent endometrial cancer from unopposed oestrogen, and letrozole for subfertility.

Pelvic Inflammatory Disease (PID) is an ascending polymicrobial infection diagnosed clinically by lower abdominal pain, purulent discharge, and exquisite cervical excitation ('chandelier sign'); first-line outpatient therapy is IM ceftriaxone 1 g stat plus oral doxycycline 100 mg BD and oral metronidazole 400 mg BD for 14 days.

Postmenopausal bleeding at age 55 or over needs a NICE NG12 suspected cancer pathway referral (consider under 55); an endometrial thickness ≥ 4 mm on transvaginal ultrasound leads to hysteroscopy and endometrial biopsy to exclude endometrial carcinoma.

Last updated: October 2026

Common Gynaecological Presentations & Gynaecological Oncology

Gynaecological symptoms, ranging from abnormal uterine bleeding and chronic pelvic pain to suspected malignancy, are frequent reasons for consultation in primary and secondary care. Applying structured diagnostic frameworks, implementing evidence-based stepped medical therapies, and recognizing oncological red flags are fundamental to clinical practice.

Heavy Menstrual Bleeding (Menorrhagia / HMB)

Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, emotional, social, and material quality of life. The International Federation of Gynecology and Obstetrics (FIGO) classifies the underlying aetiology using the PALM-COEIN framework:

Structural Causes (PALM):

  • P olyp (endometrial or endocervical polyps)
  • A denomyosis (endometrial tissue within the myometrium)
  • L eiomyoma (uterine fibroids: submucosal causing greatest bleeding, intramural, or subserosal)
  • M alignancy & hyperplasia (endometrial atypical hyperplasia and endometrial carcinoma)

Non-Structural Causes (COEIN):

  • C oagulopathy (e.g., von Willebrand disease, immune thrombocytopenia)
  • O vulatory dysfunction (e.g., polycystic ovary syndrome, perimenopause, thyroid disorders)
  • E ndometrial primary disorders (impaired local haemostasis and prostaglandin production)
  • I atrogenic (anticoagulants, copper intrauterine devices)
  • N ot yet classified
  • Clinical Investigation

Full Blood Count (FBC) & Ferritin: To identify microcytic hypochromic iron-deficiency anaemia.

Pelvic Examination: Speculum (visualise cervix, exclude polyps or cancer) and bimanual palpation (assess uterine size, contour, and mobility).

Pelvic Ultrasound (TVUS & Transabdominal): Indicated if the uterus is palpable abdominally, pelvic masses are suspected, or symptoms persist despite first-line pharmaceutical therapy.

Stepped Medical Management (NICE NG88)

Treatment Step Modality & Administration Clinical Indications & Mechanisms

First-Line (Contraception Desired) Levonorgestrel-Releasing Intrauterine System (52 mg LNG-IUS / Mirena) First-line choice when contraception is acceptable and no uterine cavity distortion exists. Locally releases levonorgestrel, inducing profound endometrial decidualisation and glandular atrophy; reduces blood loss by up to 90%

First-Line (Non-Hormonal / Desires Conception) Tranexamic Acid (1 g TDS–QDS during menses) or Mefenamic Acid (500 mg TDS during menses) Antifibrinolytic (tranexamic acid: prevents plasminogen activation) or NSAID (mefenamic acid: inhibits cyclooxygenase and endometrial prostaglandin synthesis, relieving dysmenorrhoea and reducing bleeding by 20–30%)

Second-Line Hormonal Options Combined Oral Contraceptive Pill (COCP) or Long-course Oral Progestogens COCP prevents endometrial proliferation and provides cycle control; oral progestogens (norethisterone 5 mg TDS from days 5–26) suppress the hypothalamic-pituitary-ovarian axis

Third-Line / Pre-Surgical GnRH Agonists (e.g., Goserelin / Leuprorelin) Induces temporary pharmacological menopause to shrink large fibroids prior to surgery

Surgical Interventions Endometrial Ablation , Uterine Artery Embolisation (UAE) , Myomectomy , or Hysterectomy Ablation is suitable if family is complete and uterus < 10 weeks size; myomectomy preserves fertility for large fibroids; hysterectomy is the definitive curative procedure

  • Endometriosis & Adenomyosis
  • Endometriosis

Endometriosis is characterized by the presence of functioning endometrial stroma and glands outside the uterine cavity, most commonly affecting the ovaries, uterosacral ligaments, pouch of Douglas, and pelvic peritoneum.

Pathophysiology: Ectopic endometrial tissue undergoes cyclical proliferation, ischaemic shedding, and localized bleeding in response to ovarian oestrogen and progesterone, triggering chronic inflammation, neuroangiogenesis, and dense fibrous adhesions.

Clinical Presentation (The Classic 4 Ds):

Dysmenorrhoea: Severe, progressive cyclical pelvic pain starting days before menses.

Deep Dyspareunia: Sharp pelvic pain during or following sexual intercourse.

Dyschezia: Painful defecation, particularly exacerbated during menstruation.

Dysuria: Cyclical urinary discomfort or hematuria.

Chronic non-cyclical pelvic pain and subfertility are also prominent.

Clinical Examination: Fixed, retroverted, tender uterus; tender nodularity along the uterosacral ligaments and pouch of Douglas; enlarged tender adnexa (ovarian endometriomas / "chocolate cysts").

Diagnostic Standard: Diagnostic laparoscopy with histological biopsy is the gold standard. Pelvic TVUS and MRI can identify endometriomas and deep infiltrating nodules but cannot exclude superficial peritoneal disease.

Management:

Analgesia: First-line NSAIDs (ibuprofen, mefenamic acid) and paracetamol.

Hormonal Suppression: Continuous COCP, oral progestogens, or the 52 mg LNG-IUS to induce amenorrhoea. GnRH agonists with "add-back" low-dose HRT (to prevent osteoporosis and vasomotor symptoms) for refractory disease.

Surgical Excision: Laparoscopic excision or ablation of endometriotic lesions and adhesiolysis to restore anatomy and improve fertility.

Adenomyosis

Adenomyosis is the invasion of endometrial tissue directly into the uterine myometrium, causing myometrial hypertrophy and hyperplasia. It characteristically presents in multiparous women aged 35–50 with heavy menstrual bleeding and severe dysmenorrhoea. On examination, the uterus is symmetrically enlarged, globular, soft, and uniformly tender (unlike the irregular, firm, non-tender contours of fibroids). First-line therapy is the LNG-IUS; definitive cure is hysterectomy.

Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome (PCOS) is a complex metabolic and endocrine disorder characterized by chronic anovulation, androgen excess, and insulin resistance.

Rotterdam Diagnostic Criteria

Diagnosis requires the presence of at least 2 out of the following 3 criteria , after excluding other causes of hyperandrogenism (such as congenital adrenal hyperplasia, Cushing's syndrome, and androgen-secreting tumours):

Oligo- or Anovulation: Menstrual cycles lasting > 35 days, fewer than 9 cycles per year, or complete amenorrhoea.

Clinical and/or Biochemical Hyperandrogenism:

Clinical: Hirsutism (excessive terminal hair growth in male-pattern distribution, evaluated by Ferriman-Gallwey score), severe persistent acne, androgenic alopecia.

Biochemical: Elevated total serum testosterone, elevated Free Androgen Index (FAI), or elevated androstenedione.

Polycystic Ovaries on Ultrasound: TVUS demonstrating ≥ 20 follicles (measuring 2–9 mm) per ovary and/or an increased ovarian volume ≥ 10 mL in either ovary.

Metabolic & Oncological Considerations

Insulin Resistance: Present in up to 70% of women with PCOS regardless of BMI; compensatory hyperinsulinaemia stimulates ovarian theca cells to produce excess androgens and suppresses hepatic sex hormone-binding globulin (SHBG) synthesis, magnifying free testosterone levels.

Endometrial Protection: Chronic anovulation leads to continuous, unopposed oestrogen stimulation of the endometrium without luteal progesterone production. This dramatically elevates the risk of endometrial hyperplasia and endometrial carcinoma . Women with amenorrhoea or oligomenorrhoea must be induced to have at least 3 to 4 withdrawal bleeds per year .

Clinical Management

Lifestyle & Weight Reduction: Foundational first-line for all overweight patients. A 5–10% body weight reduction improves insulin sensitivity, restores regular ovulatory cycles, and reduces androgen levels.

Endometrial Protection & Menstrual Regulation: Combined oral contraceptive pill (particularly preparations with anti-androgenic progestogens such as co-cyprindiol / Dianette, or drospirenone / Yasmin), cyclical oral progestogens (medroxyprogesterone 10 mg for 14 days every 1–3 months), or the LNG-IUS.

Metabolic Management: Metformin improves peripheral insulin sensitivity and glucose tolerance.

Subfertility: Weight optimisation is paramount; Letrozole (aromatase inhibitor) is the first-line ovulation-inducing agent, with clomifene citrate as an alternative.

Pelvic Inflammatory Disease (PID)

Pelvic Inflammatory Disease is an ascending polymicrobial infection of the upper female genital tract involving the endometrium, fallopian tubes, ovaries, and pelvic peritoneum.

Aetiology: Sexually transmitted pathogens predominate, led by Chlamydia trachomatis , Neisseria gonorrhoeae , and Mycoplasma genitalium , frequently complicated by endogenous anaerobic and facultative vaginal flora.

Clinical Presentation: Bilateral lower abdominal/pelvic pain, abnormal or purulent vaginal discharge, deep dyspareunia, abnormal post-coital or intermenstrual bleeding, and pyrexia (> 38°C).

Physical Examination: Cervical motion tenderness (the "chandelier sign") , bilateral adnexal tenderness, and uterine tenderness on bimanual examination.

Clinical Diagnostic Approach: A low threshold for empirical treatment is mandatory. Awaiting laboratory swab results is dangerous; untreated or delayed treatment rapidly causes irreversible tubal damage.

Long-Term Complications: Tubal-factor subfertility (12% after 1 episode, rising to > 50% after 3 episodes), ectopic pregnancy (6-fold increased risk), chronic pelvic pain, tubo-ovarian abscess, and Fitz-Hugh-Curtis syndrome (perihepatitis causing right upper quadrant pain and "violin-string" fibrous adhesions between the liver capsule and anterior abdominal wall).

First-Line Outpatient Antimicrobial Regimen (BASHH Guidelines)

Intramuscular Ceftriaxone 1 g stat (single IM injection with 1% lidocaine) — ensures potent bactericidal coverage against N. gonorrhoeae .

Oral Doxycycline 100 mg twice daily for 14 days — provides reliable intracellular coverage against C. trachomatis and M. genitalium .

Oral Metronidazole 400 mg twice daily for 14 days — treats anaerobic bacteria and concurrent bacterial vaginosis.

Partner Management: Contact tracing and empirical treatment of all sexual partners within the preceding 60 days. Sexual abstinence is advised until both patient and partner complete treatment.

Gynaecological Oncology Red Flags & Suspected Cancer Referrals

NICE NG12 uses the suspected cancer pathway (formerly called the "2-week wait"; NHS England now measures a 28-day faster diagnosis standard):

Gynaecological Cancer Red Flag (NICE NG12) Primary Care Action & Diagnostic Pathway

Endometrial Cancer Postmenopausal bleeding (PMB): unexplained vaginal bleeding more than 12 months after menstruation stopped because of the menopause Refer on the suspected cancer pathway if aged 55 or over ; consider referral if under 55. Transvaginal ultrasound: an endometrial thickness ≥ 4 mm (or recurrent bleeding) leads to hysteroscopy and endometrial biopsy (Pipelle)

Cervical Cancer Appearance of the cervix consistent with cervical cancer on examination (ulceration, exophytic mass, contact bleeding) Consider a suspected cancer pathway referral, regardless of screening history; persistent post-coital or intermenstrual bleeding needs speculum examination

Ovarian Cancer Ascites and/or a pelvic or abdominal mass (not obviously fibroids) Refer urgently on the suspected cancer pathway

Ovarian Cancer (symptoms) Persistent or frequent (more than 12 times a month) bloating, early satiety or loss of appetite, pelvic or abdominal pain, or urinary urgency or frequency, especially in women aged 50 or over Measure serum CA125 ; if ≥ 35 U/mL , arrange urgent ultrasound of the abdomen and pelvis and refer if it suggests ovarian cancer. In secondary care, a Risk of Malignancy Index (RMI I) of 250 or more means referral to a specialist gynaecological oncology MDT (NICE CG122)

Vulval Cancer Unexplained vulval lump, ulceration or bleeding Consider a suspected cancer pathway referral; persistent lichen sclerosus changes not responding to treatment need specialist review and biopsy

NHS Cervical Screening Programme Protocol

Recall Intervals: Since 1 July 2025 in England (2020 in Scotland, 2022 in Wales), people aged 25–64 who test hrHPV-negative are recalled every 5 years (previously 3-yearly for ages 25–49).

Primary Screening Modality: High-risk Human Papillomavirus ( hrHPV ) testing on liquid-based cytology samples.

Clinical Pathway:

hrHPV Negative: Return to routine 5-yearly recall.

hrHPV Positive with Normal Cytology: Repeat HPV test in 12 months. If hrHPV remains positive at 12 months with normal cytology, repeat at 24 months. If hrHPV remains positive at 24 months, refer directly for colposcopy .

hrHPV Positive with Abnormal Cytology (Borderline, Low-grade, or High-grade Dyskaryosis): Direct urgent referral for colposcopy .

Other Gynaecological Presentations

Cervical ectropion: columnar epithelium visible on the ectocervix, common in pregnancy, adolescence and with the combined pill; it can cause discharge and post-coital bleeding . Confirm cervical screening is up to date and exclude infection and cancer; treatment (for example cryotherapy) is only for troublesome symptoms.

Ovarian torsion: sudden severe unilateral lower abdominal pain with nausea and vomiting , often with an ovarian cyst or mass (including in pregnancy or after ovarian stimulation). Doppler ultrasound can show normal flow , so clinical suspicion leads to urgent laparoscopy to untwist and preserve the ovary.

Loading diagram... Gynaecological Diagnostic & Management Pathways